

General information about company		
Scrip code*	530125	
NSE Symbol*	NOTLISTED	
MSEI Symbol*	NOTLISTED	
ISIN*	INE103E01016	
Name of company	Samrat Pharmachem Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	13-08-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	23-06-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	First quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended		
Segment Reporting	Single segment	
Description of single segment	Pharmaceutical Chemicals	
Start date and time of board meeting	13-08-2025 14:00	
End date and time of board meeting	13-08-2025 21:00	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	There are no defaults in payment of Loans

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-06-2025	30-06-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	7565.16	7565.16	
	Other income	69.13	69.13	
	Total income	7634.29	7634.29	
2	Expenses			
(a)	Cost of materials consumed	8251.71	8251.71	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-912.71	-912.71	
(d)	Employee benefit expense	50.78	50.78	
(e)	Finance costs	43.79	43.79	
(f)	Depreciation, depletion and amortisation expense	17	17	
(g)	Other Expenses			
1	Manufacturing, Administration, Selling & Distribution Expense	162.94	162.94	
	Total other expenses	162.94	162.94	
	Total expenses	7613.51	7613.51	
3	Total profit before exceptional items and tax	20.78	20.78	
4	Exceptional items	0	0	
5	Total profit before tax	20.78	20.78	
6	Tax expense			
7	Current tax	0.09	0.09	
8	Deferred tax	43.58	43.58	
9	Total tax expenses	43.67	43.67	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	-22.89	-22.89	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	-22.89	-22.89	
17	Other comprehensive income net of taxes	0	0	
18	Total Comprehensive Income for the period	-22.89	-22.89	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			

	Paid-up equity share capital	308.97	308.97	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	-0.74	-0.74	
	Diluted earnings (loss) per share from continuing operations	-0.74	-0.74	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	-0.74	-0.74	
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.74	-0.74	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block

Textual Information(4)

- 1. The above results were reviewed by the Audit Committee of the Board of Directors.
- 2. The above results have been taken on record by the Board of Directors at it Meeting held on Wednesday, August 13, 2025 at the Corporate Office of the Company.
- 3. The Company manufactures pharmaceutical chemicals, which is a single business segment.
- 4. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

Other Comprehensive Income			
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	0.00	0.00